OBJECTIVES

: The prevalence of coronary artery disease (CAD) in diabetic patients is 25.6% and the incidence of acute myocardial infarction (AMI) is approximately 0.17% per year in Turkey. In this study, the aim was to calculate the direct annual medical cost of AMI due to T2DM from the national healthcare payer's (SSI) perspective.

METHODS

: According to the cost of illness methodology, direct annual costs were calculated for T2DM-induced AMI. Local epidemiological data and unit costs of individual health sources were used. Comorbidities, complications, and adverse effects from treatments were included in the AMI cost and weighted by frequency of incidence. Purchasing power parity was used as currency ($PPP1=1.37 TL; OECD2017).

RESULTS

: Coronary angiography was the method of scanning in 90% of cases in Turkey; 67% of the patients received a percutaneous coronary intervention (PCI) and 6% underwent coronary by-pass grafting (CABG). Thrombolytic treatment was given in 27% of cases. The mean PCI cost was $2,587.0. The mean cost of CABG procedure was $5,467.8. The AMI annual mean cost per person was $6,044.6 and the annual monitoring cost for CAD for subsequent years was $895.1. AMI disease cost consisted of 49.0% medical intervention costs, 22.2% hospital costs and 12.5% medication costs. The remainder was formed of 6.4% for comorbidities, 4.8% for follow-up, and 4.7% for complications. Medication constituted 85% of the cost for subsequent years.

CONCLUSIONS

: In Turkey, 1,983,154 T2DM patients have CAD and 13,170 T2DM patients develop an AMI. The cost of an AMI was $79,607,897 and the yearly cost of CAD was $1,854,677,923 due to T2DM. T2DM-induced AMI carries an annual cost of $1.8 billion, which represents a major economic burden.